N-Ethyltryptamine
N-Ethyltryptamine (NET), also abbreviated as NETP, is a tryptamine that is structurally related to N-methyltryptamine (NMT) and the psychedelic drugs N,N-dimethyltryptamine (DMT) and N,N-diethyltryptamine (DET).[1]
Use and effects
Alexander Shulgin included NET as an entry in his book TiHKAL (Tryptamines I Have Known and Loved).[1] However, he stated that it had been subjected only to modest human trials and that no active dose level had been identified.[1]
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | IA |
| 5-HT2A | 38 (EC50) 99% (Emax) |
| SERT | 19a (EC50) |
| NET | 3,862a (EC50) |
| DAT | 6,660a (EC50) |
| Notes: The smaller the value, the more avidly the drug interacts with the site. Footnotes: a = Neurotransmitter release. Sources: [2] | |
NET has been found to act as a potent serotonin 5-HT2A receptor full agonist and a selective serotonin releasing agent.[2] It is inactive at the 5-HT1A receptor.[2]
Chemistry
Synthesis
The chemical synthesis of NET has been described.[1]
Analogues
Analogues of NET include N-methyltryptamine (NMT), dimethyltryptamine (DMT), methylethyltryptamine (MET), and diethyltryptamine (DET), among others.[1]
See also
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".
External links
Template:Serotonin receptor modulators Template:Monoamine releasing agents Script error: No such module "Navbox".